There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Soleno Therapeutics (SLNO – Research Report), Agilon Health (AGL – Research Report) and Integer Holdings (ITGR – Research Report) with bullish sentiments.
Soleno Therapeutics (SLNO)
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Soleno Therapeutics, with a price target of $47.00. The company’s shares closed last Friday at $40.25, close to its 52-week high of $40.74.
According to TipRanks.com, Gershell is a 2-star analyst with an average return of
Soleno Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $48.67.
See the top stocks recommended by analysts >>
Agilon Health (AGL)
Benchmark Co. analyst Bill Sutherland maintained a Buy rating on Agilon Health today and set a price target of $22.00. The company’s shares closed last Friday at $12.55, close to its 52-week low of $10.41.
According to TipRanks.com, Sutherland has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Agilon Health with a $19.21 average price target.
Integer Holdings (ITGR)
Benchmark Co. analyst Robert Wasserman maintained a Buy rating on Integer Holdings today and set a price target of $105.00. The company’s shares closed last Friday at $99.08, close to its 52-week high of $100.99.
According to TipRanks.com, Wasserman is a 1-star analyst with an average return of
Currently, the analyst consensus on Integer Holdings is a Moderate Buy with an average price target of $95.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SLNO:
- Best-Performing Stocks of 2023: Can They Keep On Rolling?
- Soleno Therapeutics’ CEO Bhatnagar sells $3.3M in company shares
- Oppenheimer, Wedbush say buy these biotech stocks for 2024
- Soleno Therapeutics assumed with a Buy rating, $40 target at Guggenheim
- Soleno Therapeutics assumed with a Buy at Guggenheim
